FibroBiologics, Inc.

PharmaceuticalsBiotechnologyClinical-stageFibroblast therapies

📍 Houston, TX, United States

StreetZero Signal 62

Be the first to signal interest

About FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company based in Houston developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds 160-275+ US and internationally issued patents and pending patents across pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, and cancer. Its pipeline includes candidates such as CYWC628 for wound healing, CYMS101 for multiple sclerosis, CybroCell for degenerative disc disease, and CYPS317 for psoriasis. Net proceeds from financings support R&D programs and a planned Phase 1/2 diabetic foot ulcer clinical trial.

LATEST FUNDINGPrivate Placement

$1.2M

Announced 2026-10-13

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for FibroBiologics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED—

HQHouston, TX, United States

Industry

Pharmaceuticals

Investors

Yorkville Advisors

Key highlights

Closed multiple tranches of a $25 million financing plus a $3 million public offering and post-IPO equity raises.
Pipeline targets wound healing, multiple sclerosis, degenerative disc disease, and psoriasis with fibroblast-derived candidates.
Holds 160-275+ issued and pending patents across multiple clinical indications.
Preparing for a Phase 1/2 diabetic foot ulcer trial expected to start in the second half of 2025.
R&D spend increased to $3.0 million in Q1 2026 driven by CRO costs for clinical preparation.

Ask StreetZero about FibroBiologics, Inc.

Put our AI to work on this deal.

What is FibroBiologics, Inc.'s value proposition?Who are FibroBiologics, Inc.'s competitors?Why does this raise matter?Summarize FibroBiologics, Inc. for an investor.

Similar companies

Other Pharmaceuticals deals, ranked by Signal.

EIKONOKLASTES THERAPEUTICS, INC.

$16.1M

LUCIER PHARMACEUTICALS INC

$2.0M

Vimy Pharmaceuticals Inc.

$1.0M

Thetis Pharmaceuticals LLC

$560K

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.